Analytical Data
-
基因名
HLA-A*02:01&B9M&Survivin(TLPPAWQPFL) Monomer
- Application
-
别名
BIRC5; API4; EPR-1; Baculoviral Inhibitor Of Apoptosis Repeat Containing 5; Apoptosis Inhibitor 4; Survivin Variant 3 Alpha
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O15392
-
表达区间
Met1~Asp142
-
分子量
22kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01&B9M&Survivin (TLPPAWQPFL) monomer recombinant protein emerges as a pivotal tool in immunological research, particularly in cancer immunotherapy and vaccine development. Survivin, an anti-apoptotic protein, is often overexpressed in various cancers, making it a compelling target for immune response modulation. The TLPPAWQPFL peptide, derived from the survivin protein, is known to bind effectively to the HLA-A*02:01 molecule, a prevalent human leukocyte antigen (HLA) class I allele. This interaction is critical as it presents the survivin epitope to CD8+ T cells, which can recognize and destroy cancer cells expressing survivin. By engineering a monomeric form of this complex, researchers aim to study the specific binding characteristics and stability of the peptide-HLA interaction, facilitating deeper insights into T cell activation mechanisms. Such studies not only advance the understanding of survivin's role in tumor immunology but also pave the way for innovative therapeutic strategies, including peptide-based vaccines that can elicit robust anti-tumor responses in HLA-A*02:01 positive patients. Overall, the HLA-A*02:01&B9M&Survivin monomer represents a significant advancement in the quest to harness the immune system against cancer by targeting tumor-associated antigens.
